Prospective dynamic molecular residual disease analysis of perioperative nivolumab in resectable NSCLC: data from the CTONG1804 phase 2 clinical trial (ESMO Asia 2026) - Oct 1, 2026 - Abstract #918P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • P2 data • Residual disease • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|
|
Wei-Chi Luo; Si-Yang M. Liu; Song Dong; Qing Zhou; Chen Huang; Xuening Yang; Benyuan Jiang; Jun-Tao Lin; Ri-Qiang Liao; Qiang Nie; Xiao S. Ben; Xueying Zhang; Jiayan Wu; Hong-Hong Yan; L Yan; Wenzhao Zhong; Yi-Long Wu
|